Jarina 3 mg/0,03 mg FC tablets.
PDF Leaflet Revision Date: 11 July 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Oral contraception.
Dosage (summary)
One tablet daily for 28 days, starting on day 1 of the menstrual cycle.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not indicated during pregnancy; not recommended during breastfeeding.
Key Drug Interactions
- Enzyme inducers (e.g., phenytoin, rifampicin)
- CYP3A4 inhibitors (e.g., ketoconazole, erythromycin)
Contraindications
- Hypersensitivity
- Thromboembolic events
- Severe hepatic disease
- Severe renal insufficiency
- Undiagnosed vaginal bleeding
- Pregnancy
Common side effects
- Depression
- Migraine
- Nausea
- Breast pain
- Unscheduled bleeding
Counselling Points
- Take at the same time daily
- Use barrier method if pills are missed
- Consult physician for mood changes
Serious warnings
- Increased risk of thromboembolic events
- Monitor blood pressure
- Potential for liver tumors
Important Disclaimer
The Jarina 3 mg/0,03 mg FC tablets. professional information leaflet below is the property of Bayer and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
